A randomized phase 3 study to evaluate the efficacy and safety of daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (cybord) compared with cybord alone in newly diagnosed systemic al amyloidosis
2016-001737-27Amiloidosis AL (amiloidosis sistémica AL diagnosticada recientemente)Fundación Jiménez DíazInvestigador: Askari Askari Elham
